Ocugen
Open
$1.21
Prev. Close
$1.21
High
$1.22
Low
$1.21
Market Snapshot
$396.76M
-5.5
-0.21
$4.06M
116
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 116 full-time employees. The company went IPO on 2014-12-03. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. The company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. The company is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 116 full-time employees. The company went IPO on 2014-12-03. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. The company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. The company is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Recently from Cashu
Ocugen Gains Investor Optimism After Oppenheimer's Outperform Rating and $10 Price Target
Ocugen's Strategic Position Sparks Investor Optimism Ocugen Inc., a biotechnology firm focused on developing innovative therapies in the ocular disease space and vaccines for infectious diseases, find…
Ocugen Attracts Investor Interest After Positive Oppenheimer Coverage and $10 Price Target
Ocugen Sees Positive Surge in Interest Following Oppenheimer Analyst Coverage Ocugen Inc. garners renewed attention in the biotechnology sector after Oppenheimer analyst Leland Gershell initiates cove…
Ocugen's Commitment to Ocular Health Innovation Amid Growing Industry Demand and Trends
Ocugen's Strategic Focus on Ocular Health Innovation Amidst Growing Industry Trends Ocugen (NASDAQ: OCGN) positions itself as a significant player within the biopharmaceutical landscape, particularly…
Ocugen's Strategic Innovations and Partnerships in the Biopharmaceutical Sector
Ocugen's Strategic Advances in the Biopharmaceutical Sector In the rapidly evolving biopharmaceutical industry, Ocugen is positioning itself to capitalize on significant opportunities in the market. T…